Promotion
mRNA 15% OFF + Buy NTPs, get DNase I
RNase Inhibitor
| Catalog No. | ON-039 |
| Purity | ＞95% by SDS-PAGE |
| Storage Condition | -20℃ |
| Source | Recombinant E.coli |
RNase Inhibitor
RNase Inhibitor - M (Molecular Biology) / Non-GMP / 40kU / centrifuge tube is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
Shipping notes
Shipping notes
Details
Details
Product Information
Ribonuclease Inhibitor, Human Placenta is a recombinant human placental protein with specifically inhibits broad-spectrum RNase such as RNase A, RNase B and RNase C. It is not effective against RNase 1, RNase T1, S1 Nuclease, RNase H, Taq DNA polymerase, M-MLV Reverse Transcriptase and T7 RNA Polymerase. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at 1:1 ratio. The Ki value for binding of Ribonuclease Inhibitor, Human Placenta to RNase is approximately 10-14M.
Source: Recombinant E.coli
Concentration: 40U/μL
Unit Definition: One unit is defined as the amount of Recombinant Ribonuclease Inhibitor required inhibit the activity of 5ng of ribonuclease A by 50%. Activity is measured by the inhibition of hydrolysis of cytidine 2',3'-cyclic monophosphate by ribonuclease A.
Storage Buffer: 20mM HEPES-KOH (pH7.6), 50mM KCl, 8mM DTT, 50%(v/v) glycerol.
Key points of operation
- Ribonuclease Inhibitor is active over a broad pH range (pH5.5-9).
- Ribonuclease Inhibitor is used in the standard RT and in vitro transcription, and the final concentration is 1U/μL.
Security Information
Storage Conditions: -20℃
Quality Assurance: Free of endonuclease, exonuclease, Nickase, RNase and latent RNase activities.
Physical Purity: ＞95% by SDS-PAGE.
Reference
1. Blackburn, P., Wilson, G. and Moore,S. J. Biol. Chem. 252, 5904-10(1977).
Specifications
Specifications
-
Catalog No.ON-039ON-039-G
-
SourceRecombinant E.coliRecombinant E.coli
-
Purity＞95% by SDS-PAGE＞95% by SDS-PAGE
-
Storage Condition-20℃-20℃
Documentation
Documentation
Product Information
Ribonuclease Inhibitor, Human Placenta is a recombinant human placental protein with specifically inhibits broad-spectrum RNase such as RNase A, RNase B and RNase C. It is not effective against RNase 1, RNase T1, S1 Nuclease, RNase H, Taq DNA polymerase, M-MLV Reverse Transcriptase and T7 RNA Polymerase. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at 1:1 ratio. The Ki value for binding of Ribonuclease Inhibitor, Human Placenta to RNase is approximately 10-14M.
Source: Recombinant E.coli
Concentration: 40U/μL
Unit Definition: One unit is defined as the amount of Recombinant Ribonuclease Inhibitor required inhibit the activity of 5ng of ribonuclease A by 50%. Activity is measured by the inhibition of hydrolysis of cytidine 2',3'-cyclic monophosphate by ribonuclease A.
Storage Buffer: 20mM HEPES-KOH (pH7.6), 50mM KCl, 8mM DTT, 50%(v/v) glycerol.
Key points of operation
- Ribonuclease Inhibitor is active over a broad pH range (pH5.5-9).
- Ribonuclease Inhibitor is used in the standard RT and in vitro transcription, and the final concentration is 1U/μL.
Security Information
Storage Conditions: -20℃
Quality Assurance: Free of endonuclease, exonuclease, Nickase, RNase and latent RNase activities.
Physical Purity: ＞95% by SDS-PAGE.
Reference
1. Blackburn, P., Wilson, G. and Moore,S. J. Biol. Chem. 252, 5904-10(1977).
-
Catalog No.ON-039ON-039-G
-
SourceRecombinant E.coliRecombinant E.coli
-
Purity＞95% by SDS-PAGE＞95% by SDS-PAGE
-
Storage Condition-20℃-20℃
Why choose Hongene?
Trusted Partner in Nucleic Acid
Integrated Supply & Commercial Scale
With nearly 30 years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.
Proprietary Technology & IP
Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.
Rigorous Quality
We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.
Manufacturing Scalability
Hongene operates 1.67 million sq. ft Oligonucleotide Manufacturing Facility, with advanced equipments including multiple OligoPilot™ and OligoProcess™ synthesizers (10-1800 mmol). 48 flexible production lines enable one-stop seamless scaling-up of API production from gram-level to tons and acheive high purity of 98%, meeting NMPA, FDA, and EMA standards.
Global Business Network
Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.
